Recently, three EZH2 inhibitors have been observed in clinical trials including CPI-1205 in B-Cell Lymphomas, E7438 in Advanced Solid Tumors/B Cell Lymphomas and GSK2816126 in Relapsed/ Refractory Diffuse Large B Cell and Transformed Follicular Lymphomas [19]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.